Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
In calculating the Net-Net Working Capital (NNWC), Benjamin Graham assumed that a company's accounts receivable is only worth 75% its value, its inventory is only worth 50% of its value, but its liabilities have to be paid in full. In addition, Graham believed that preferred stock belongs on the liability side of the balance sheet, not as part of capital and surplus. This is a conservative way of estimating the company's value.
Wakamoto Pharmaceutical Co's Net-Net Working Capital for the quarter that ended in Mar. 2026 was 円60.18.
The industry rank for Wakamoto Pharmaceutical Co's Net-Net Working Capital or its related term are showing as below:
TSE:4512's Price-to-Net-Net-Working-Capital is ranked better than 67.01% of 394
companies
in the Drug Manufacturers industry
Industry Median: 8.215
vs TSE:4512: 4.80
Wakamoto Pharmaceutical Co (TSE:4512) Net-Net Working Capital Explanation
One research study, covering the years 1970 through 1983 showed that portfolios picked at the beginning of each year, and held for one year, returned 29.4 percent, on average, over the 13-year period, compared to 11.5 percent for the S&P 500 Index. Other studies of Graham's strategy produced similar results.
Benjamin Graham looked for companies whose market values were less than two-thirds of their net-net value. They are collected under our Net-Net screener.
Wakamoto Pharmaceutical Co Net-Net Working Capital Related Terms
Wakamoto Pharmaceutical Co Net-Net Working Capital Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Wakamoto Pharmaceutical Co Net-Net Working Capital Chart
TSE:4512 vs ZTS: Net-Net Working Capital Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Wakamoto Pharmaceutical Co's Price-to-Net-Net-Working-Capital, along with its competitors' market caps and Price-to-Net-Net-Working-Capital data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Wakamoto Pharmaceutical Co Price-to-Net-Net-Working-Capital vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Wakamoto Pharmaceutical Co's Price-to-Net-Net-Working-Capital distribution charts can be found below:
* The bar in red indicates where Wakamoto Pharmaceutical Co's Price-to-Net-Net-Working-Capital falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In calculating the Net-Net Working Capital (NNWC), Benjamin Graham assumed that a company's accounts receivable is only worth 75% its value, its inventory is only worth 50% of its value, but its liabilities have to be paid in full.
In addition, Graham believed that preferred stock belongs on the liability side of the balance sheet, not as part of capital and surplus. In "Security Analysis", preferred stock is dubbed "an imperfect creditorship position" that is best placed on the balance sheet alongside funded debt.
This is a conservative way of estimating the company's value.
What does a Net-Net Working Capital of 円60.18 mean?
Wakamoto Pharmaceutical Co (TSE:4512) has a Net-Net Working Capital of 円60.18 as of Mar. 2026. Ben Graham defined net-net working capital as the per-share sum of cash, 75% of receivables and 50% of inventory less total liabilities. View historical data on Wakamoto Pharmaceutical Co According to the industry distribution chart, Wakamoto Pharmaceutical Co ranks #130 out of 394 companies in the Drug Manufacturers industry, placing it in the top 33%.
Is Wakamoto Pharmaceutical Co's Net-Net Working Capital too high?
Wakamoto Pharmaceutical Co's current Net-Net Working Capital is 円60.18. Based on the distribution chart, Wakamoto Pharmaceutical Co ranks #130 out of 394 companies in the Drug Manufacturers industry, which is above the industry midpoint. Overall, Wakamoto Pharmaceutical Co has a GF Score™ of 64/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Wakamoto Pharmaceutical Co's Net-Net Working Capital compare to ZTS?
According to the Drug Manufacturers industry distribution chart, Wakamoto Pharmaceutical Co ranks #130 out of 394 companies for Net-Net Working Capital. This puts Wakamoto Pharmaceutical Co in the upper half of its industry. The industry median Net-Net Working Capital is 8.22. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Net-Net Working Capital for a Drug Manufacturers company?
The median Net-Net Working Capital among Drug Manufacturers companies is 8.22, based on 394 companies in the industry. Companies in the top quartile (top 25%) have a Net-Net Working Capital significantly above this median, while those in the bottom quartile fall well below. However, Net-Net Working Capital should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Net-Net Working Capital mean?
A high Net-Net Working Capital can signal that a stock is expensive relative to its fundamentals. Ben Graham defined net-net working capital as the per-share sum of cash, 75% of receivables and 50% of inventory less total liabilities. View historical data on Wakamoto Pharmaceutical Co For the Drug Manufacturers industry, the median Net-Net Working Capital is 8.22 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Wakamoto Pharmaceutical Co's current Net-Net Working Capital is 円60.18. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Wakamoto Pharmaceutical Co stock overvalued right now?
Based on GuruFocus' analysis, Wakamoto Pharmaceutical Co (TSE:4512) is currently considered Fairly Valued. The stock's GF Value™ is 円309.66, compared to a current price of 円306.00 — trading 1.2% below its estimated fair value. The current Net-Net Working Capital is 円60.18. Wakamoto Pharmaceutical Co's overall GF Score™ is 64/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Net-Net Working Capital calculated?
Net-Net Working Capital is calculated from a company's financial statements. For Wakamoto Pharmaceutical Co (TSE:4512), the current Net-Net Working Capital is 円60.18 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Wakamoto Pharmaceutical Co (TSE:4512) Overvalued in 2026?
Based on GuruFocus' analysis, Wakamoto Pharmaceutical Co stock appears to be undervalued.
The current stock price of 円306.00 is trading 1.2% below its estimated GF Value™ of 円309.66.
GuruFocus considers Wakamoto Pharmaceutical Co to be Fairly Valued.
Key valuation signals for TSE:4512:
Net-Net Working Capital: 円60.18
GF Value™: 円309.66 vs. price of 円306.00 (1.2% below fair value)
No single metric tells the full story. See the TSE:4512 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Wakamoto Pharmaceutical Co Ltd is the pharmaceutical company based in Japan. It is engaged in the research and development, production and sale of ethical drugs and non-prescription drugs. The company specializes in therapeutic and diagnostic agents for ophthalmic disorders. It offers Strong Wakamoto, a gastrointestinal drug for digestion, the intestinal function controlling, and nutritional supply.
64GF Score
Get the complete analysis for TSE:4512
Net-Net Working Capital is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
TSE:4512 has been successfully added to your 
